Telomerase activity analyzed with TRAP in situ provides additional information in effusions remaining equivocal after immunocytochemistry and hyaluronan analysis

Diagnostic Cytopathology

Volumn 42, Issue 12, 2014, Pages 1051-1057

  Adell, Elisabet ^a   Dejmek, Annika ^a,b  

^a University and Regional Laboratories   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Cytodiagnosis; Molecular diagnostic techniques; Peritoneal effusion; Pleural effusion; Telomerase; TRAP in situ

Indexed keywords

HYALURONIC ACID; TELOMERASE;

ADENOCARCINOMA; ADULT; AGED; AMYLOIDOSIS; ARTICLE; ASSAY; CANCER CELL; CLINICAL ARTICLE; CYTOLOGY; DIAGNOSTIC VALUE; EFFUSION; ENZYME ACTIVITY; EPITHELIAL MALIGNANT MESOTHELIOMA; FEMALE; HUMAN; IMMUNOCYTOCHEMISTRY; MALE; MALIGNANT MESOTHELIOMA; MALIGNANT NEOPLASTIC DISEASE; MESENCHYMAL MALIGNANT MESOTHELIOMA; RECEIVER OPERATING CHARACTERISTIC; SQUAMOUS CELL CARCINOMA; TELOMERE REPEAT AMPLIFICATION PROTOCOL IN SITU; VERY ELDERLY; ASCITES FLUID; CYTODIAGNOSIS; EXUDATE; GENETICS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MESOTHELIOMA; MIDDLE AGED; PATHOLOGY; PLEURAL EFFUSION, MALIGNANT; PROCEDURES; TELOMERE;

AGED; AGED, 80 AND OVER; ASCITIC FLUID; CYTODIAGNOSIS; EXUDATES AND TRANSUDATES; FEMALE; HUMANS; HYALURONIC ACID; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL EFFUSION, MALIGNANT; TELOMERASE; TELOMERE;

EID: 84911375764     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.23165     Document Type: Article

References (35)

1. Grefte JM, de Wilde PC, Salet-van de Pol MR, Tomassen M, Raaymakers-van Geloof WL, Bulten J. Improved identification of malignant cells in serous effusions using a small, robust panel of antibodies on paraffin-embedded cell suspensions. Acta Cytol 2008; 52: 35-44.
2. Dejmek A, Hjerpe A. Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: Stepwise logistic regression analysis. Cytopathology 2000; 11: 8-17.
3. Dejmek A, Hjerpe A. The combination of CEA, EMA, and BerEp4 and hyaluronan analysis specifically identifies 79% of all histologically verified mesotheliomas causing an effusion. Diagn Cytopathol 2005; 32: 160-166.
4. Nurminen M, Dejmek A, Martensson G, Thylen A, Hjerpe A. Clinical utility of liquid-chromatographic analysis of effusions for hyaluronate content. Clin Chem 1994; 40: 777-780.
5. Metzgeroth G, Kuhn C, Schultheis B, Hehlmann R, Hastka J. Diagnostic accuracy of cytology and immunocytology in carcinomatous effusions. Cytopathology 2008; 19: 205-211.
6. Mohanty SK, Dey P. Serous effusions: Diagnosis of malignancy beyond cytomorphology. An analytic review. Postgrad Med J 2003; 79: 569-574.
7. Sriram KB, Relan V, Clarke BE, et al. Diagnostic molecular biomarkers for malignant pleural effusions. Future Oncol 2011; 7: 737-752.
8. Shen YC, Chen ZN, Yang T, et al. Telomerase activity assay for the diagnosis of malignant pleural effusion: A meta-Analysis. Exp Ther Med 2012; 4: 487-492.
9. Braunschweig R, Guilleret I, Delacretaz F, Bosman FT, Mihaescu A, Benhattar J. Pitfalls in TRAP assay in routine detection of malignancy in effusions. Diagn Cytopathol 2001; 25: 225-230.
10. Braunschweig R, Yan P, Guilleret I, et al. Detection of malignant effusions: Comparison of a telomerase assay and cytologic examination. Diagn Cytopathol 2001; 24: 174-180.
11. Cha N, Li XY, Zhao YJ, Wang EH, Wu GP. hTERT Gene amplification and clinical significance in pleural effusions of patients with lung cancer. Clin Lung Cancer 2012; 13: 494-499.
12. Dikmen G, Dikmen E, Kara M, Sahin E, Dogan P, Ozdemir N. Diagnostic implications of telomerase activity in pleural effusions. Eur Respir J 2003; 22: 422-426.
13. Hess JL, Highsmith WE. Telomerase detection in body fluids. Clin Chem 2002; 48: 18-24.
14. Hiroi S, Nakanishi K, Kawai T. Expressions of human telomerase mRNA component (hTERC) and telomerase reverse transcriptase (hTERT) mRNAin effusion cytology. Diagn Cytopathol 2003; 29: 212-216.
15. Li WD, Ni YM, Tu ZL, Wu SJ, Wu ZY, Zheng SS. Study of telomerase activity in pleural lavage fluid specimens in patients with non-small-cell lung cancer and its clinical significance. Eur J Cardiothorac Surg 2009; 36: 460-464.
16. Nieh S, Chen SF, Fu E, Jan CI, Lee WH. Detection of the human telomerase RNA component by in situ hybridization in cells from body fluids. Acta Cytol 2005; 49: 31-37.
17. Shu J, Sun GY, Liu AP, Liu J. Diagnostic accuracy of human telomerase reverse transcriptase mRNA in malignant pleural effusions: A preliminary report for in situ hybridization detection. Clin Chim Acta 2007; 381: 131-135.
18. Tangkijvanich P, Tresukosol D, Sampatanukul P, et al. Telomerase assay for differentiating between malignancy-related and nonmalignant ascites. Clin Cancer Res 1999; 5: 2470-2475.
19. Toshima S, Arai T, Yasuda Y, et al. Cytological diagnosis and telomerase activity of cells in effusions of body cavities. Oncol Rep 1999; 6: 199-203.
20. Yang CT, Lee MH, Lan RS, Chen JK. Telomerase activity in pleural effusions: Diagnostic significance. J Clin Oncol 1998; 16: 567-573.
21. Rhyu MS. Telomeres, telomerase, and immortality. J Natl Cancer Inst 1995; 87: 884-894.
22. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33: 787-791.
23. Shay JW, Wright WE. Telomerase activity in human cancer. Curr Opin Oncol 1996; 8: 66-71.
24. Piatyszek MA, Kim NW, Weinrich SL, et al. Detection of telomerase activity in human cells and tumors by a telomeric repeat amplification protocol (TRAP). Methods Cell Sci 1995; 17: 1-15.
25. Ohyashiki K, Ohyashiki JH, Nishimaki J, et al. Cytological detection of telomerase activity using an in situ telomeric repeat amplification protocol assay. Cancer Res 1997; 57: 2100-2103.
26. Dejmek A, Yahata N, Ohyashiki K, et al. In situ telomerase activity in pleural effusions: A promising marker for malignancy. Diagn Cytopathol 2001; 24: 11-15.
27. Zendehrokh N, Dejmek A. Telomere repeat amplification protocol (TRAP) in situ reveals telomerase activity in three cell types in effusions: Malignant cells, proliferative mesothelial cells, and lymphocytes. Mod Pathol 2005; 18: 189-196.
28. WHO. International classification of diseases ICD 10; 2007. World Health Organiation, http://www.who.int/classifications/icd/en/.
29. Counter CM, Gupta C, Harley CB, Leber B, Bacchetti S. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood 1995; 85: 2315-2320.
30. Norrback KF, Dahlenborg K, Carlsson R, Roos G. Telomerase activation in normal B lymphocytes and non-Hodgkin's lymphomas. Blood 1996; 88: 222-229.
31. Liu K, Schoonmaker MM, Levine BL, June CH, Hodes RJ, Weng NP. Constitutive and regulated expression of telomerase reverse transcriptase (hTERT) in human lymphocytes. Proc Natl Acad Sci USA 1999; 96: 5147-5152.
32. Henson JD, Neumann AA, Yeager TR, Reddel RR. Alternative lengthening of telomeres in mammalian cells. Oncogene 2002; 21: 598-610.
33. Dhaene K, Hubner R, Kumar-Singh S, Weyn B, Van Marck E. Telomerase activity in human pleural mesothelioma. Thorax 1998; 53: 915-918.
34. Villa R, Daidone MG, Motta R, et al. Multiple mechanisms of telomere maintenance exist and differentially affect clinical outcome in diffuse malignant peritoneal mesothelioma. Clin Cancer Res 2008; 14: 4134-4140.
35. Barberis M, Pellegrini C, Cannone M, Arizzi C, Coqqi G, Bosari S. Quantitative PCR and HER2 testing in breast cancer: A technical and cost-effectiveness analysis. Am J Clin Pathol 2008; 129: 563-570.